Endoscopic Mucosal Resection Valuable for Cancer Diagnosis Endoscopic Mucosal Resection Valuable for Cancer Diagnosis
Surgeons should perform EMR for all visible lesions in the presence of neoplasia to make an accurate histopathologic diagnosis of early-stage esophageal cancer, said a physician at GICS 2022.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 27, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Pembro+Chemo as First-Line Standard of Care for Esophageal Cancer Pembro+Chemo as First-Line Standard of Care for Esophageal Cancer
An additional 12 months of follow-up confirmed the benefits of the combination therapy as a first-line treatment for advanced or metastatic esophageal cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 21, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

MVision, Medron Medical ink distribution agreement
Radiotherapy treatment planning software developer MVision AI has entered int...Read more on AuntMinnie.comRelated Reading: IMV: Radiation therapy capital equipment budgets up 21% in 2021 New radiotracer improves management of prostate cancer patients Cancer mortality declined by 27% over past five decades New radiation therapy tools are highlight of ASTRO 2021 Consider the esophagus when it comes to breast cancer radiotherapy (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 3, 2022 Category: Radiology Source Type: news

New data from the phase II CITYSCAPE trial show encouraging results with Roche ’s novel anti-TIGIT tiragolumab plus Tecentriq
Basel, 10 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new follow-up efficacy, safety and patient-reported outcomes (PROs) data from the phase II CITYSCAPE trial, investigating the novel anti-TIGIT cancer immunotherapy tiragolumab plus Tecentriq ® (atezolizumab) compared with Tecentriq alone as an initial (first-line) treatment for people with PD-L1-positive metastatic non-small cell lung cancer (NSCLC). The full results are being featured as an oral presentation in the Proffered Paper session 2 (Abstract LBA2) at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2021, taking ...
Source: Roche Media News - December 10, 2021 Category: Pharmaceuticals Source Type: news

New data from the phase II CITYSCAPE trial show encouraging results with Roche ’s novel anti-TIGIT tiragolumab plus Tecentriq
Basel, 10 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new follow-up efficacy, safety and patient-reported outcomes (PROs) data from the phase II CITYSCAPE trial, investigating the novel anti-TIGIT cancer immunotherapy tiragolumab plus Tecentriq ® (atezolizumab) compared with Tecentriq alone as an initial (first-line) treatment for people with PD-L1-positive metastatic non-small cell lung cancer (NSCLC). The full results are being featured as an oral presentation in the Proffered Paper session 2 (Abstract LBA2) at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2021, taking ...
Source: Roche Investor Update - December 10, 2021 Category: Pharmaceuticals Source Type: news

Throat cancer symptoms: Key signs of cancer that affect your throat and voice
THROAT CANCER is the name sometimes given to cancers affecting the thyroid, larynx, oesophagus or trachea. What are the symptoms to look out for? (Source: Daily Express - Health)
Source: Daily Express - Health - November 29, 2021 Category: Consumer Health News Source Type: news

Esophageal Cancer Requires Long-term Postop Surveillance Esophageal Cancer Requires Long-term Postop Surveillance
Endoscopic resection of T1 esophageal adenocarcinoma is associated with excellent overall survival, yet long-term surveillance is still required for possible recurrence.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 19, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Bone fractures are common after breast cancer endocrine therapy
Wrist and vertebral fractures are most prevalent in women who have receive...Read more on AuntMinnie.comRelated Reading: Screening, socioeconomic status linked to breast cancer mortality U.S. cancer care financial burden hit $21B in 2019 Improvements needed in breast cancer screening for Black women Consider the esophagus when it comes to breast cancer radiotherapy Radiation therapy for breast cancer boosts risk of heart disease (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 17, 2021 Category: Radiology Source Type: news

Mayo Clinic Minute: Stomach cancer concerns
Stomach cancer, also called gastric cancer, is an abnormal growth of cells that begins in the stomach. It can affect several areas of the stomach, including the main stomach lining or where the esophagus meets the stomach. November is Stomach Cancer Awareness Month, and experts at Mayo Clinic say there is hope for patients with the disease as treatments continue to improve. Watch: The Mayo Clinic Minute https://youtu.be/hAexmiycYOA Journalists: Broadcast-quality video (1:20) is in the… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - November 11, 2021 Category: Databases & Libraries Source Type: news

Mayo Clinic Q & amp;A podcast: Using the immune system to treat stomach cancer
Stomach cancer, also known as gastric cancer, can affect any part of the stomach. In most of the world, stomach cancers form in the main part of the stomach. But in the U.S., stomach cancer is more likely to affect the area where the esophagus meets the stomach. This area is called the gastroesophageal junction.  Where the cancer occurs in the stomach is one factor doctors consider when determining treatment options. Treatment usually includes surgery to… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - November 1, 2021 Category: Databases & Libraries Source Type: news

Advances in the Treatment of Gastric Cancer: 2020-2021 Advances in the Treatment of Gastric Cancer: 2020-2021
This review presents an update of recent advances in the treatment of esophageal and gastric cancers, including the use of immune checkpoint inhibitor therapy as first-line treatment.Current Opinion in Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 25, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

What is Refeeding Syndrome?
Discussion Anorexia nervosa is an eating disorder with an intense fear of being overweight (i.e. distorted body image), and self-starvation and excessive weight loss. It is more common in women (1.2%) than men (0.2%) but can be seen in both genders. Risk factors include high-intelligence, perfectionism/inflexibility, anxiety, activities where thinner body types are expected (e.g. dancer, diver, gymnast, long-distance runner, volleyball player, etc.) Other eating disorders include bulimia nervosa (i.e. cycles of binge eating and then purging), binge eating disorder (i.e. purging), orthorexia (i.e. obsessions with healthful ...
Source: PediatricEducation.org - October 25, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Mystery of the environmental triggers for cancer deepens
Study shows that our knowledge of why tumours form is still inadequateScientists will have to rethink howenvironmental triggers allow tumours to form and develop, one of Britain ’s leading cancer experts warned last week. Michael Stratton, director of the Wellcome Sanger Institute, said recent results from an international cancer research study – which aimed to pinpoint environmental triggers involved in oeosophageal cancer – indicated current scientific understanding of tumour formation was inadequate.The research – on a type known as oesophageal squamous cell carcinoma – was aimed at uncovering why certain part...
Source: Guardian Unlimited Science - October 24, 2021 Category: Science Authors: Robin McKie Tags: Cancer research Medical research UK news Science Source Type: news

Cernostics CEO on the opportunities ahead with Castle's acquisition
The Pittsburgh-based company's lead product is Tissue Cypher, which uses artificial intelligence and spatial biology to help physicians determine who of the patients diagnosed with a type of esophageal damage, Barrett's Esophagus, will go on to develop esophageal cancer. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - October 22, 2021 Category: Health Management Authors: Paul J. Gough Source Type: news

Pittsburgh-based biotech firm Cernostics acquired for $30M
Pittsburgh-based biotech firm Cernostics will be acquired by Castle Biosciences Inc. in a deal worth at least $30 million. Castle (Nasdaq: CSTL) could pay up to $50 million more in cash and common stock depending on 2022 performance milestones. Cernostics Inc. uses artificial intelligence and spatial biology to analyze tissue biopsies through its platform TissueCypher Barrett's Esophagus Assay. The test Cernostics ha s developed detects the development of esophageal cancer and high-grade dysplasia… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 20, 2021 Category: Pharmaceuticals Authors: Paul J. Gough Source Type: news